[go: up one dir, main page]

WO2008033326A3 - Méthode destinée à déterminer le traitement d'individus présentant un site fragile - Google Patents

Méthode destinée à déterminer le traitement d'individus présentant un site fragile Download PDF

Info

Publication number
WO2008033326A3
WO2008033326A3 PCT/US2007/019702 US2007019702W WO2008033326A3 WO 2008033326 A3 WO2008033326 A3 WO 2008033326A3 US 2007019702 W US2007019702 W US 2007019702W WO 2008033326 A3 WO2008033326 A3 WO 2008033326A3
Authority
WO
WIPO (PCT)
Prior art keywords
individuals
fragile site
determining treatment
determining
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019702
Other languages
English (en)
Other versions
WO2008033326A2 (fr
Inventor
Lionel J Coignet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of WO2008033326A2 publication Critical patent/WO2008033326A2/fr
Publication of WO2008033326A3 publication Critical patent/WO2008033326A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes destinées à déterminer une chimiothérapie pour un individu chez lequel un cancer a été diagnostiqué ou la présence d'un cancer suspectée, ainsi qu'une méthode destinée à faciliter l'élaboration d'un plan thérapeutique pour un individu et à déterminer si un agent chimiothérapeutique peut induire une rupture d'un site fragile FRA12E.
PCT/US2007/019702 2006-09-11 2007-09-11 Méthode destinée à déterminer le traitement d'individus présentant un site fragile Ceased WO2008033326A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84365706P 2006-09-11 2006-09-11
US60/843,657 2006-09-11

Publications (2)

Publication Number Publication Date
WO2008033326A2 WO2008033326A2 (fr) 2008-03-20
WO2008033326A3 true WO2008033326A3 (fr) 2008-12-11

Family

ID=39184288

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019702 Ceased WO2008033326A2 (fr) 2006-09-11 2007-09-11 Méthode destinée à déterminer le traitement d'individus présentant un site fragile

Country Status (1)

Country Link
WO (1) WO2008033326A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078136A1 (fr) * 2004-02-06 2005-08-25 Health Research, Inc. Methode de pronostic de metastase par la detection du site fragile de fra12e dans le locus du gene smrt au niveau du chromosome 12q24

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005078136A1 (fr) * 2004-02-06 2005-08-25 Health Research, Inc. Methode de pronostic de metastase par la detection du site fragile de fra12e dans le locus du gene smrt au niveau du chromosome 12q24

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HOUDE C. ET AL.: "The Presence of the FRA12E/SMRT Fragile Site in the Genome of Prostate Cancer (CaP) Patients is a Predictor of Metastatic Development", FIRST AACR INTERNATIONAL CONFERENCE ON MOLECULAR DIAGNOSTICS IN CANCER THERAPEUTIC DEVELOPMENT, September 2006 (2006-09-01), pages ABSTR. NO. A60 *

Also Published As

Publication number Publication date
WO2008033326A2 (fr) 2008-03-20

Similar Documents

Publication Publication Date Title
WO2008039944A3 (fr) procÉdÉ et dispositif permettant l'insertion d'un dÉtecteur d'analytes
WO2006107848A3 (fr) Appareil et procedes de detection de l'emplacement et de la migration de conducteurs de neurostimulation
WO2008002672A3 (fr) Cibles utilisées pour le diagnostic, le pronostic et la thérapie du cancer
IL180997A0 (en) Diagnostic methods and kits utilizing platelet biomarkers for cancer
WO2008140774A3 (fr) Procédés de diagnostic et de traitement du cancer de la prostate et du cancer du poumon
NO20090028L (no) Fremgangsmåter og systemer for bestemmelse av inntrengning i reservoarsoner
NO20082960L (no) Ligander med bindingsspesifisitet for VEGF og/eller EGFR og fremgangsmater for anvendelse derav
WO2008088579A3 (fr) Détection d'une obstruction microvasculaire et thérapie correspondante
IL191538A0 (en) Method for diagnosing, prognosing and treating glioma
IS8770A (is) Plástrar, kerfi og aðferðir fyrir ei-ífarandi glúkósa mælingu
EP1755754A4 (fr) Systeme et procede de pari reposant sur des indicateurs de marche financier
EP2527466A3 (fr) Variants génétiques du CHR2 utilisés comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
WO2006047787A3 (fr) Methode de surveillance de la progression ou la recurrence d'une maladie
WO2008067291A3 (fr) Méthodes et appareils de gestion du contrôle du glucose
EP2074422A4 (fr) Methodes et trousses de detection de marqueurs du cancer de la prostate
EP2099083A4 (fr) Corps laminé à couche mince, capteur magnétique à couche mine utilisant le corps laminé à couche mince et procédé de fabrication du corps laminé à couche mince
WO2008027218A3 (fr) Électrotransport de médicament avec une mesure d'hydratation d'un réservoir hydratable
PL2073864T5 (pl) Urządzenie i sposób odzyskiwania krwi
SG121040A1 (en) Method and system for detecting leak in electronicdevices
WO2008011519A3 (fr) Inhibiteurs d'amigo-2 pour le traitement, le diagnostic ou la détection du cancer
WO2009036427A3 (fr) Biomarqueurs du cancer de la prostate
WO2008131361A3 (fr) Biocapteurs pour mesurer des analytes dans le liquide interstitiel
IL185668A0 (en) Novel anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor
WO2007103146A3 (fr) Protéines tronquées comme marqueurs de cancer
WO2006086442A3 (fr) Methode de detection de tissu anormal

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07838006

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07838006

Country of ref document: EP

Kind code of ref document: A2